Dme Capital Management, LP Gain Therapeutics, Inc. Transaction History
Dme Capital Management, LP
- $1.94 Trillion
- Q4 2024
A detailed history of Dme Capital Management, LP transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Dme Capital Management, LP holds 566,130 shares of GANX stock, worth $1.08 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
566,130
Previous 566,130
-0.0%
Holding current value
$1.08 Million
Previous $1.01 Billion
21.35%
% of portfolio
0.06%
Previous 0.04%
Shares
1 transactions
Others Institutions Holding GANX
# of Institutions
30Shares Held
2.69MCall Options Held
5.7KPut Options Held
10.6K-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$1.12 Million0.1% of portfolio
-
Geode Capital Management, LLC Boston, MA267KShares$508,0990.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA177KShares$336,4420.0% of portfolio
-
Joel Greenblatt Gotham Asset Management, LLC | New York, Ny158KShares$300,4940.0% of portfolio
-
Telemetry Investments, L.L.C. New York, NY123KShares$233,7000.61% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $22.6M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...